- Posts: 25
- Thank you received: 0
1. You must be a registered website user in order to post and comment. Guests may read only.
2. Be kind and helpful, not rude and cynical.
3. Don't advertise or promote anything. You will be banned from the group.
4. Report problems to the moderators. THANK YOU!
Sharonwo37 wrote: however, it is likely there are other reasons due to being a heart transplant recipient, blockages, and other medical issues he has to use the Retuxin instead.
The 6 month response rate was 60%, so overall, 55% enjoyed a 12 month response, and 45% a 24 month response.ww.bloodjournal.org/content/early/2015/05/13/blood-2015-03-631937
A novel triple therapy for ITP using high dose dexamethasone, low dose rituximab and cyclosporine (TT4)
Key Points:
- Triple therapy is well tolerated and effective in patients with chronic ITP.
- Relapse free survival was 92% for responders after 12 months and 76% after 24 months.
www.jwatch.org/na37941/2015/05/20/triple-therapy-refractory-immune-thrombocytopenia
Triple Therapy for Refractory Immune Thrombocytopenia
David Green, MD, PhD reviewing Choi PY et al. Blood 2015 May 13.
Relapse-free survival was 92% at 12 months in patients who received dexamethasone, rituximab, and cyclosporine.
Corticosteroids are the initial treatment for adults with primary immune thrombocytopenia (ITP) and platelet counts of <30 × 109/L; second-line therapies include splenectomy, thrombopoietin-receptor agonists, and rituximab (NEJM JW Oncol Hematol Jun 2011 and Blood 2011; 117:4190). Rituximab selectively depletes B-lymphocytes, but whether suppressing T-lymphocytes with cyclosporine would further improve outcomes has not been evaluated.
Now, Australian investigators have conducted a phase IIb study in which 20 ITP patients who had received ≥2 lines of prior therapy were treated with a single course of triple therapy with oral dexamethasone 40 mg on days 1–4), intravenous rituximab (100 mg on days 7, 14, 21, and 28), and oral cyclosporine (2.5–3.0 mg/kg/daily on days 1–28, titrated to a blood level of 200–400 µg/L). Additional courses of dexamethasone were given if the platelet response was delayed.
The platelet count increased to ≥30 × 109/L (measured on two occasions >7 days apart) in 60% of patients; the median time to response was 7.4 days. The relapse-free survival rates at 12 months and 24 months were 92% and 76%, respectively. Factors significantly associated with response at 6 months were male gender,prior lines of therapy, and an initial platelet response by day 28 or day 60. Therapy-related grade III or IV adverse effects were hypertension in three patients and a wound infection in one patient; there were no deaths.
COMMENT
Although the response rate in this trial (60%) was similar to that reported previously with second-line rituximab (NEJM JW Oncol Hematol Apr 2015 and Lancet 2015 Apr 25; 385:1653), relapse-free survival was longer, probably due to cyclosporine suppression of reactive T-cells. In addition, the short duration of therapy and relatively mild toxicity further commend this approach. The next step should be a phase III trial comparing dexamethasone plus rituximab with this triple-therapy regimen.
The Platelet Disorder Support Association does not provide medical advice or endorse any medication, vitamins or herbs. The information contained herein is not intended nor implied to be a substitute for professional medical advice and is provided for educational purposes only. Always seek the advice of your physician or other qualified healthcare provider before starting any new treatment, discontinuing an existing treatment and to discuss any questions you may have regarding your unique medical condition.
Platelet Disorder Support Association
8751 Brecksville Road, Suite 150, Cleveland, Ohio 44141
Phone: 1-87-PLATELET | 877-528-3538 (toll free) | or 440-746-9003
E-mail: pdsa@pdsa.org
© Copyright 1997 - 2025, Platelet Disorder Support Association. All rights reserved.
The Platelet Disorder Support Association is a 501(c)3 organization and donations are tax deductible to the fullest extent allowed by law.